Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Phytopharm plc
Godmanchester, Cambridgeshire, UKphytopharm.co.uk ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
As of the last public reports, Phytopharm had two main clinical-stage products—Cogane™ and Myogane™—both orally active neurotrophic factor modulators. Cogane™ was in development as a potential disease-modifying agent for Parkinson’s, Alzheimer’s, and Huntington’s diseases. Myogane™ targeted ALS and other orphan neurodegenerative conditions. Additional preclinical programs included candidates for asthma/COPD and vascular dementia. The company was publicly listed but has since ceased operations; its website and trading are no longer active.
- Therapeutic areas
- PulmonologyNeurology
- Modalities
- Small molecules (neurotrophic factors)
- Industry
- Biotech
Beyond the preview
Go deeper on Phytopharm plc.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Phytopharm plc.